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Summary Dose limiting systemic toxicity prevents sufficient exploitation of the steep dose response relation-
ship of most anticancer agents. In our rat liver tumour model (the CC531 colorectal carcinoma), isolated liver
perfusion allows administration of higher doses of mitomycin C than hepatic artery infusion, while systemic
toxicity remains minimal. To determine the temporal pattern of mitomycin C induced cytokinetic changes, we
analysed flow cytometric DNA histograms of CC531 liver tumours from rats treated with high dose
mitomycin C (3.2 mg kg-') via hepatic artery infusion and sacrificed at different time intervals after treatment.
Between 12 and 36 h after treatment, the fraction of cells in late S and G2/M phase had markedly increased.
The effects of administration of the respective maximally tolerated doses of mitomycin C in isolated liver
perfusion and via hepatic artery infusion on progression of tumour cells through the cell cycle and on gross
tumour growth were compared. Isolated liver perfusion with mitomycin C resulted in a significant increase in
the proportion of cells in mid and late S, and in some accumulation of cells in early S and G2/M phase at 24
and 48 h after treatment. In contrast, after hepatic artery infusion a significant increase of the fraction of cells
in G2/M phase was observed at 24 h after treatment. Monitoring tumour growth after isolated liver perfusion
five out of seven rats showed a complete tumour remission, while after hepatic artery infusion only a minimal
growth delay was detected. This study demonstrates that isolated liver perfusion in the rat CC531 liver tumour
model allows the administration of a well-tolerated dose of mitomycin C being high enough to induce a
marked DNA synthesis inhibition and even complete tumour remission.
Colorectal cancer is one of the most common malignant
tumours (Silverberg & Lubera, 1987). The liver is the major
site of metastatic spread and in 40% of the patients also the
sole site of initial recurrence (Cohen et al., 1989, pp. 906). If
the liver metastases are resectable, resection results in a 5
year survival rate of about 35% (August et al., 1985; Iwat-
suki et al., 1986). If not resectable the 5 year survival rate
with untreated hepatic metastases is less than 5% (Wagner et
al., 1984). These patients are eligible for regional therapies.
The goal of regional cancer chemotherapy is to obtain high
local concentrations of antitumour agents, while maintaining
relatively low drug concentrations in the systemic circulation;
inasmuch as dose-response curves of most cytostatic agents
are steep, exposure of tumour cells to higher concentrations
may have a significant impact on the effectiveness of treat-
ment.
Hepatic artery infusion with fluoropyrimidines, currently
the most effective drugs in colorectal cancer treatment
(Moertel, 1978) met with some success (Balch et al., 1983)
albeit with considerable dose limiting morbidity (van de
Velde et al., 1988, pp 163). In order to test the applicability
of isolated liver perfusion for dose escalation of a variety of
drugs, a perfusion technique was developed (de Brauw et al.,
1988) in the rat. In this study, we evaluated the effect of
mitomycin C, which has a steep dose-response relationship
(Mitra & Maillova, 1986; Wallner & Li, 1987; de Bruijn et
al., 1988) and has been reported to be a promising drug for
colorectal cancer (Doll et al., 1985; Schneider et al., 1989). In
a previous study (Marinelli et al., 1990), it was determined
that in isolated liver perfusion a four times higher dose of
mitomycin C could be administered than via hepatic artery
infusion, resulting in a five times higher concentration in
tumour tissue. In the present study, we investigated whether
this higher tissue concentration is also more effective in the
actual elimination of tumour cells.
Since changes in cell cycle progression are a sensitive
indicator for the intracellular effects of cytostatic drugs (Gray
et al., 1987, pp. 93), we evaluated changes in DNA distribu-
tions of mitomycin C treated tumours by flow cytometry.
Effects on tumour growth were studied by sequential caliper
measurements.
Materials and methods
Tumour model
The WAG rat tumour cell line CC531 is a dimethyl-hydra-
zine induced carcinoma of the colon and is weakly immuno-
genic (Marquet et al., 1984). Cells are maintained in culture
in RPMI 1640 (Dutch modification; GIBCO Europe B.V.,
Breda, The Netherlands), supplemented with 10% foetal calf
serum (GIBCO Limited, Paisley, Scotland), 2 mM L-gluta-
mine, 50 ,lg ml-' streptomycin and 50 IU ml1 penicillin.
Male WAG/Ola rats weighing 250-300 g were inoculated
with cells from cultures between passages 105-115. For in
vivo inoculation, exponentially growing cells were collected
by trypsinisation. The rats underwent laparotomy and 5.105
cells in 0.05ml Hanks Balanced Salt Solution (University
Hospital, Leiden, The Netherlands) were subcapsularly
injected in the right and left main lobe of the liver. These rats
had tumours at both sites of inoculation without extrahepatic
tumour growth. The mean cross sectional area of these
tumours (it x 0.25 x largest diameter x perpendicular dia-
meter) on day 10 was 37 ± 13 mm2.
Surgicalprocedures
Isolated liver perfusion and hepatic artery infusion are de-
scribed elsewhere (Marinelli et al., 1990). Briefly: in the
isolated liver perfusion two inflow limbs of the isolated circuit
were established by cannulation of the pyloric branch of the
portal vein and the gastroduodenal branch of the common
hepatic artery. The outflow limb was a cannula inserted in
the caval vein via a venotomy just above the right renal vein.
Isolation of the liver was achieved by clamping the caval
vein, just beneath the diaphragm and just above the right
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renal vein, the aorta above the coeliac axis and the common
hepatic artery plus portal vein. The flow into the portal vein
was 20 ml min-' and 4.5 ml min-' into the hepatic artery.
The drug was injected as a bolus in the isolated circuit.
Recirculation of the perfusate in the in vivo perfusion was
25 min. At the end of the ILP procedure a washout was
performed with 8 ml saline of 37°C, which was perfused.
through the liver using the pyloric vein cannula only. Total
operation time was 2.0-2.5 h. Hepatic artery infusion was
performed via the cannulated gastroduodenal branch of the
common hepatic artery with its tip in the hepatic artery.
During the bolus infusion the common hepatic artery was
clamped to prevent retrograde flow into the coeliac axis and
aorta. Total operation time was 30-40 min.
Flow cytometry
To determine the temporal patterns of mitomycin C induced
changes in DNA distributions of hepatic CC531 tumours
shortly after the onset of treatment, a series of 21 tumour
bearing rats was treated with high dose of mitomycin C
(Kyowa Hakko Kogyo Co. Ltd, Tokyo, Japan) via hepatic
artery infusion. At respectively 3, 6, 12, 18, 24, 36 and 48 h
rats were sacrificed and tumour samples were analysed by
flow cytometry.
Dose response patterns were studied by comparing the
effect of the respective maximally tolerated dose of mito-
mycin C as delivered by hepatic artery infusion and isolated
liver perfusion. In this study, 26 rats with two tumours each
were randomly assigned to five groups that were sacrificed
24 h after treatment: (1) untreated control (n = 4); (2) HAI
without drug (n = 4); (3) ILP without drug (n = 4); (4) 1.2 mg
kg-' MMC by HAI (n = 8) and; (5) 4.8 mg kg-' by ILP
(n = 6). Additionally, rats were sacrificed 48 h after ILP with
4.8 mgkg-' MMC (n=4).
Immediately after sacrifice, both tumours were excised,
finely minced, diluted in citrate buffer (0.04 M, pH 7.6) with
5% dimethylsulfoxide (Vindelov et al., 1983), and frozen at
-70°C. Prior to analysis the samples were thawed and cen-
trifugated at 2,000 r.p.m. for 15 min. Suspensions of single
nuclei were prepared according to the detergent-trypsin pro-
cedure described by Vindelov et al. (1983), and stained with
propidium iodide (Sigma, St Louis, MO).
Samples were analysed on a FACScan flow cytometer
(Becton & Dickinson, Mountain View, CA). Propidium iodide
(PI) fluorescence was excited at 488 nm and measured at
585 nm. Cell cycle distributions were calculated with aid of
the CellFIT Software using the Sum of Broadened Rectan-
gles (SOBR) model. However, this model as well as the R-fit
and S-fit model gave erratic results for the highly distorted
DNA distributions in part of the experiments. For this
reason, histograms are presented without calculations of the
percentages of cells in the different cell cycle compartments.
However, cells were counted three channels either side of
1.25 xGl, 1.5 xGI (=mid S), 1.75 xGI and 2.0xGl
(= G2/M) to achieve a more objective evidence on accumula-
tion of cells in S and G2/M phase.
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Tumour growth
To study the effects of mitomycin C on tumour growth,
tumour bearing rats (two tumours each) were randomly
assigned to: (1) untreated control (n = 6); (2) hepatic artery
infusion without drug (n = 4); (3) isolated liver perfusion
without drug (n = 4); (4) hepatic artery infusion with 1.2 mg
kg-' (n = 7), and (5) isolated liver perfusion with 4.8 mg kg-'
(n = 7). On days 0 (day of treatment), 14, 28 and 42 rats were
weighed and in order to measure liver tumours laparotomy
was performed. Cross sectional tumour areas were estimated
by caliper measurements and calculated as: i x 0.25 x length
x width.
Statistical evaluation
Statistical significance was determined by one-way analysis of
variance using the SPSS package. To compare each treatment
group with the control group the option contrast was used
with separate variance estimates. A P value <0.01 was
selected to denote statistical significance between groups.
Results
Effects ofmitomycin C on cell cycle distribution
Flow cytometric DNA histograms of CC531 liver tumours at
different time intervals after 3.2 mgkg-' mitomycin C (as
delivered by hepatic artery infusion) revealed a significant
increase of the proportion of cells in the late S and G2/M
phase between 12 and 36 h after treatment (Figures 1 and
2a). At 48 h, the histograms closely resembled those of the
control group (baseline values: GO/GI: 64-± 3%, S: 30 ± 4%
and G2/M: 6 ± 2%). Therefore, 24h was chosen as time
interval for the evaluation of dose response relationships.
Histograms obtained with tumour cells collected after
hepatic artery infusion or isolated liver perfusion without
drug (Figures 2b, 3 II and III, respectively) were identical to
those obtained from tumours of untreated control rats
(Figures 2b and 3 1). After treatment with 1.2 mg kg-' via
hepatic artery infusion, the proportion of cells in G2/M
phase was significantly increased (Figures 2b and 3 IV).
However, in late S phase no accumulation of cells was seen
after treatment with 1.2 mg kg-', while late S was signi-
ficantly increased after treatment with 3.2 mg kg' (Figures
1, 2a and b). Treatment with 4.8 mg kg- mitomycin C in
isolated liver perfusion resulted in a significant accumulation
of tumour cells in mid and late S phase and also in some
accumulation in early S and in G2/M phase (Figures 2b and
3 V). Forty-eight hours after treatment mid and late S phase
were still significantly increased and there was still an accum-
ulation ofcells in early S and in G2/M phase (Figures 2b and
3 VI).
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Figure 1 Flow cytometric DNA histograms of CC531 colorectal carcinoma cells treated with 3.2 mgkg-' via hepatic artery
infusion and obtained from liver tumours at different time intervals after treatment: 0, 3, 6, 12, 18, 24, 36 and 48 h after treatment.
For each time interval, histograms of tumours from two different rats are shown.76 A. MARINELLI et al.
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Effects ofmitomycin C on tumour growth
Figure 4 shows growth patterns of CC531 liver tumours.
Tumour growth was not influenced by the in- or perfusion
procedures without mitomycin C (compare Figure 4a, b and
c, respectively). In most rats the tumours had reached a
lethal size at day 42. After the maximally tolerated dose of
mitomycin C via hepatic artery infusion a slight retardation
of tumour growth was observed (Figure 4d). In contrast,
after the maximally tolerated dose was delivered in an
isolated liver perfusion setting five out of seven rats showed a
complete remission from day 14 till sacrifice (Figure 4e). In
one rat one tumour regressed, but relapsed between day 14
and 28, whereas the other tumour showed a minimal growth
delay during the first 14 days. In the second non-responding
rat no growth inhibition was observed.
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Figure 2 Mean number of cells counted three channels either
side of 1.25 x G1, 1.5 x GI (= mid S), 1.75 x G1 and 2.0 x GI
(= G2/M) in the flow cytometric DNA histograms (10,000 counts
per histogram) of CC531 colorectal carcinoma cells obtained
from liver tumours (two tumours per rat) of control rats and of
rats treated with mitomycin C: a, different time intervals after
treatment with 3.2mgkg-': 0 (n=4), 3 (n=2), 6 (n=3), 12
(n= 3), 18 (n=2), 24 (n= 3), 36 (n=2) and 48 (n=3) hours
after treatment ( +- 1.25 x GI, -* 1.5 x GI, 0
1.75 x GI, x 2.0 x GI); b, + untreated control group
(n = 4), 0 24 h after hepatic artery infusion without drug (n = 4),
* 24 h after isolated liver perfusion without drug (n = 4), x 24 h
after hepatic artery infusion with 1.2 mg kg' (n = 8), O 24 h
after isolated liver perfusion with 4.8 mg kg-' (n =6), A 48 h
after isolated liver perfusion with 4.8 mg kg-' (n = 4).
* =significant difference with the control value (P<0.01).
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The primary damage produced by mitomycin C is cross-
linking of DNA thereby inhibiting DNA replication (Crooke
& Bradner, 1976). Increased intracellular concentration
results in a higher number of cross-links (Dorr et al., 1985;
Matsumoto et al., 1989). Evidently, the extent of mitomycin
C induced S phase accumulation observed in the present
study may result from the degree of cross-linking and the
influx rate of tumour cells into the S phase (Engelholm et al.,
1986). However, the sensitivity of tumour cells to mitomycin
C induced DNA damage may also depend on their ability to
remove DNA cross-links (Kaiser et al., 1982). In hepatic
artery infusion treated rats DNA cross-links apparently were
too few or removed too rapidly to result in a significant
accumulation of cells in S phase. Yet, cells became (tran-
siently?) arrested in the G2/M phase. Uninhibited progres-
sion through the S phase with subsequent arrest in the G2/M
phase indicates that the mitotic process may be profoundly
disturbed even at lower mitomycin C doses. For a number of
cytostatic agents several authors reported that tumour cells in
G2/M phase may be more sensitive to DNA damage than
cells in S phase (Tobey et al., 1975; Sorenson & Eastman,
1988a). Cells proficient in DNA repair can circumvent this
G2/M arrest by repairing damaged DNA, thereby permitting
transcription of genes required for passage into mitosis (Sor-
enson & Eastman, 1988b). This might explain the normalisa-
tion of the cell cycle distribution at 48 h after treatment.
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Figure 3 Flow cytometric DNA histograms of CC531 colorectal carcinoma cells obtained from liver tumours of control rats and
of rats treated with mitomycin C: (I) untreated control group (n = 4); (II) 24 h after hepatic artery infusion without drug (n = 4);
(III) 24 h after isolated liver perfusion without drug (n = 4); (IV) 24 h after hepatic artery infusion with 1.2 mg kg-' (n = 8); (V)
24 h after isolated liver perfusion with 4.8 mg kg-' (n = 6); and (VI) 48 h after isolated liver perfusion with 4.8 mg kg-' (n = 4). For
each group DNA profiles from three different rats are shown to demonstrate the reproducibility of the cell cycle distributions of
tumours from different rats within each group.EFFECT OF MITOMYCIN C ON RAT LIVER TUMOURS 77
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Figure 4 Growth curves of CC531 liver tumours (two tumours per rat): a, untreated control rats (n = 6); b, hepatic artery infusion
without drug (n = 4); c, isolated liver perfusion without drug (n = 4); d, rats treated with 1.2 mgkg-' (maximally tolerated dose) via
hepatic artery infusion (n = 7) and e, rats treated with 4.8 mgkg-' (maximally tolerated dose) in isolated liver perfusion setting
(n = 7). Only in the isolated liver perfusion group complete remissions were seen (five out of seven).
As could be expected from the evaluation of the temporal
pattern of cell cycle perturbation a relatively modest change
in the DNA profile was seen after treatment with the maxi-
mally tolerated dose of mitomycin C via hepatic artery
infusion. Dorr et al. demonstrated that DNA cross-linking
and cytotoxicity increase proportionally (Dorr et al., 1985).
Matsumoto et al. found that DNA repair by mitomycin C
cross-link removal gave an excellent correlation with cell
survival (Matsumoto et al., 1989). One may therefore hypo-
thesise that after treatment with 1.2 mg kg'- via hepatic
artery infusion the concentration of mitomycin C was too
low to generate enough cross-links to kill the tumour cells.
In rats treated with 4.8 mg kg-' mitomycin C in isolated
liver perfusion the concentration in tumour tissue evidently
was high enough to block DNA synthesis effectively, result-
ing in some accumulation of cells in early S and in a signi-
ficant increase of tumour cells in mid and late S phase in five
rats. In one rat however, the accumulation of tumour cells
was mainly in late S and G2/M phase (at 48 h) and to a
lesser degree in mid S. Since this was observed in both
tumours, the liver was probably less well perfused, resulting
in a lower mitomycin C concentration in tumour tissue. This
may be also true with respect to the isolated liver perfusion
treated rats showing partial or minimal response on tumour
growth.
In conclusion, we have demonstrated that in comparison
with hepatic artery infusion the higher concentrations of
mitomycin C (as achieved with isolated liver perfusion) are
effective in blocking DNA synthesis in CC531 tumour cells
and may even result in complete tumour remissions. Whether
isolated liver perfusion with mitomycin C is also effective in
the treatment of human colorectal cancer metastases in the
liver is currently under investigation in a phase I/II trial.
We thank G.M. van Brakel, Laboratory of Experimental Surgery,
and N. Kuipers-Dijkshoorn, Department ofPathology, University of
Leiden, for their technical assistance and W.P. de Jonge for prepar-
ing the manuscript. Dr A.M.M. Eggermont, Department of Surgery,
Rotterdam Cancer Center, Rotterdam, is gratefully acknowledged
for critically reading the manuscript.
This research was supported by Grant IKW88-07 from the Dutch
Cancer Foundation.
References
AUGUST, D.A., SUGARBAKER, P.H., OTrOW, R.T., GIANOLA, F.J. &
SCHNEIDER, P.D. (1985). Hepatic resection of colorectal metas-
tases. Influence of clinical factors and adjuvant intraperitoneal
5-fluorouracil via Tenckhoff catheter on survival. Ann. Surg., 201,
203.
BALCH, C.M., URIST, M.M., SOONG, S.J. & McGREGOR, M. (1983). A
prospective phase II clinical trial of continuous FUDR regional
chemotherapy for colorectal metastases to the liver using a totally
implantable drug infusion pump. Ann. Surg., 198, 567.
DE BRAUW, L.M., VAN DE VELDE, C.J.H., TJADEN, U.R. & 4 others
(1988). In vivo isolated liver perfusion technique in a rat hepatic
metastasis model: 5-fluorouracil concentrations in tumour tissue.
J. Surg. Res., 44, 137.
DE BRUIJN, E.A., SLEE, P.H.Th.J., KUPPEN, P.J.K. & 7 others (1988).
The importance ofexposure time in regional chemotherapy: mito-
mycin C and fluoropyrimidines. Contr. Oncol., 29, 43.
COHEN, A.M., SHANK, B. & FRIEDMAN, M.A. (1989). Colorectal
cancer; spread ofcolorectal cancer. In Cancer, Principles & Prac-
tice of Oncology, DeVita, V.T. Jr., Hellman, S. & Rosenberg,
S.A. (eds), 3rd edition, Chapter 29, p. 906. JB Lippincott Com-
pany: Philadelphia, USA.
CROOKE, S.T. & BRADNER, W.T. (1976). Mitomycin: a review.
Cancer Treat. Rev., 3, 121.
DOLL, D.C., WEISS, R.B. & ISSELL, B.F. (1985). Mitomycin: ten years
after approval for marketing. J. Clin. Oncol., 3, 276.
DORR, R.T., BOWDEN, G.T. & ALBERTS, D.S. (1985). Interactions of
Mitomycin C with mammalian DNA detected by alkaline elution.
Cancer Res., 45, 3510.
ENGELHOLM, S.A., SPANG-THOMSEN, M., VINDELOV, L.L. &
BRONNER, N. (1986). Chemosensitivity of human small cell car-
cinoma of the lung detected by flow cytometric DNA analysis of
drug-induced cell cycle perturbations in vitro. Cytometry, 7, 243.78 A. MARINELLI et al.
GRAY, J.W., DOLBEARE, F., PALLAVICINI, M.G. & VANDERLAAN,
M. (1987). Flow cytokinetics. In Techniques in Cell Cycle Ana-
lysis, Gray, J.W. & Darzynkiewicz, Z. (eds), p. 93. Humana
Press: Clifton, New Jersey, USA.
IWATSUKI, S., ESQUIVEL, S.O., GORDON, R.D. & STARZL, T.E.
(1986). Liver resection for metastatic colorectal cancer. Surgery,
100, 804.
KAISER, T.N., LOJEWSKI, A., DOUGHERTY, C., JUERGENS, L.,
SAHAR, E. & LATT, S.A. (1982). Flow cytometric characterization
of the response of Fanconi's anemia cells to Mitomycin C treat-
ment. Cytometry, 2, 291.
MARINELLI, A., VAN DE VELDE, C.J.H., KUPPEN, P.J.K., FRANKEN,
H.C.M., SOUVERIJN, J.H.M. & EGGERMONT, A.M.M. (1990). A
comparative study ofisolated liver perfusion versus hepatic artery
infusion with mitomycin C in rats. Br. J. Cancer, 63, (in press).
MARQUET, R.L., WESTBROEK, D.L. & JEEKEL, J. (1984). Interferon
treatment of a transplantable rat colon adenocarcinoma: impor-
tance of tumour site. Int. J. Cancer, 33, 689.
MATSUMOTO, A., VOS, J.M.H. & HANAWALT, P.C. (1989). Repair
analysis of Mitomycin induced DNA crosslinking in ribosomal
RNA genes in lymfoblastoid cells from Fanconi's anemia patients.
Mutation Res., 217, 185.
MITRA, A.K. & MAILLOVA, A. (1986). Mitomycin C pharmaco-
kinetics in rats; effect of dose size. Int. J. Pharm., 32, 133.
MOERTEL, C.G. (1978). Chemotherapy of gastrointestinal cancer. N.
Eng. J. Med., 299, 1049.
SCHNEIDER, A., KEMENY, N., CHAPMAN, D., NIEDZWIECKI, D. &
ODERMAN, P. (1989). Intrahepatic mitomycin C as a salvage
treatment for patients with hepatic metastases from colorectal
carcinoma. Cancer, 64, 2203.
SILVERBERG, E. & LUBERA, J. (1987). Cancer statistics 1987. CA J.
Phys., 37, 2.
SORENSON, C.M. & EASTMAN, A. (1988a). Mechanism of cis-diam-
minedichloroplatinum-(II)-induced cytotoxicity: role of G2 arrest
and DNA double-strand breaks. Cancer Res., 48, 4484.
SORENSON, C.M. & EASTMAN, A. (1988b). Influence of cis-diam-
minedichloroplatinum-(II) on DNA synthesis and cell cycle
progression in excision repair proficient and deficient Chinese
hamster ovary cells. Cancer Res., 48, 6703.
TOBEY, R.A. (1975). Different drugs arrest cells at a number of
distinct stages in G2. Nature, 254, 245.
VAN DE VELDE, C.J.H., DE BRAUW, L.M., SUGARBAKER, P.H. &
TRANBERG, K.G. (1988). Hepatic arterial infusion chemotherapy:
rationale, results, credits and debits. In Progress in Surgery ofthe
Liver, Pancreas and Biliary System, Bengmark, S. (ed.), p. 163.
Martinus Nijhoff Publishers: Dordrecht, Boston, Lancaster.
VINDELOV, L.L., CHRISTENSEN, I.J. & NISSEN, N.I. (1983). A deter-
gent-trypsin method for the preparation of nuclei for flow cyto-
metric DNA-analysis. Cytometry, 3, 323.
WAGNER, J.S., ADSON, M.A., VAN HEERDEN, I.A., ADSON, M.H. &
ILSTRUP, D.M. (1984). The natural history of hepatic metastases
from colorectal cancer. Ann. Surg., 199, 502.
WALLNER, K.E. & LI, G.C. (1987). Effect of drug exposure duration
and sequencing on hyperthermic potentiation of mitomycin C.
Cancer Res., 47, 493.